Life Science Leader - Home Page
WEBVolastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in ...
How To Overcome The Challenge Of Valuing A Biotech
WEBDec 30, 2019 · Companies generally use one of three common valuation frameworks to value their company: the net asset value (NAV) method, a form of the cost approach; the discounted cash flow (DCF) method, a form of the income approach; or a market approach. Biotech is better off using the NAV or DCF methods because finding comparables for the market approach ...
Where Are They Now? SQZ Biotech - lifescienceleader.com
WEBMay 1, 2024 · In 2020, Sharei took SQZ Biotech public with a $71 million IPO, and channeled the funds into its pipeline of novel cell therapies. Being the founder and CEO of SQZ Biotech was Sharei’s first full-time job, and it was “all-consuming,” noted Sharei in the 2019 article. “People often applaud entrepreneurship, lionize its leaders, and paint ...
FSP Or Full-Service Outsourcing For Clinical Trials? - Life Science …
WEBDec 3, 2013 · Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential to increase efficiency and flexibility in outsourcing without compromising quality. Well-defined services within the scope of a clinical trial project or program (e.g. data management, biostatistics, or medical writing) are good ...
What Does It Take To Succeed As A Bioentrepreneur? - Life …
WEBSep 15, 2010 · Yakatan: A four-letter word: Luck. Well, two words, luck and management. The ability to start a successful company and launch a drug requires luck and great management. shimasaki: You must have passion, vision, and persistence. The passion is your love for what you’re doing even if you’re not getting paid.
Digital Technologies Will Continue To Drive Patient Outcomes
WEBJun 1, 2021 · <p>While other companies scrambled to implement clinical trial-related technology to deal with the pandemic, Otsuka was an early adopter of tools such as eCRF and eConsent. Christoph Koenen, EVP and chief medical officer at Otsuka Pharmaceutical Companies (U.S.) explains how digital technologies will continue to drive patient outcomes.</p>
Navigating The Structured Acquisition Of The Life Sciences Company
WEBDec 7, 2010 · Navigating The Structured Acquisition Of The Life Sciences Company. By Kenneth Ehemen. Challenging capital markets and a chilled pharmaceutical company appetite for acquisitions have led to reliance on the “structured acquisition” for the exit of biotech and life sciences start-ups. Buyers in these acquisitions will typically make a ...
Merck's Continuous Process Improvement - Life Science Leader
WEBJul 1, 2014 · Merck embraced a process of continuous improvement after years of implementing Lean initiatives that yielded periodic improvements. With Lean, Six Sigma, Kaizen, Agile, total quality management, and other process improvement approaches, after an initial surge, results sometimes slipped backwards to baseline levels.
The Story Of Arrowhead Pharmaceuticals' Adversity Odyssey
WEBApr 1, 2020 · It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C., focused on creating and building new nanobiotechnology companies from university-generated science. “We talked about the deal, and then they ...
The Future of Anxiety Treatment Will Be Drastically Different
WEBMore than 40 million Americans are living with an anxiety disorder. If America's youth are a barometer for the future, research suggests the problem is only growing. The rate at which children are diagnosed with anxiety disorders has been steadily increasing, from 5.5% of all children in 2007 to 6.4% of all children by 2011.